Photodynamic diagnosis involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in surveillance of non muscle invasive bladder cancer

Photodynamic diagnosis involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in surveillance of non muscle invasive bladder cancer - Photodynamic diagnosis using hexaminolevulinate in surveillance of non-muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038906

Enrollment

100

Registered

2019-12-16

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 patients with non muscle invasive bladder cancer confirmed by transurethral resection 2 patients aged 20 and over 3 patients who plan to commute Nara Medical University for follow-up.

Exclusion criteria

Exclusion criteria: 1 patients who received cystectomy 2 patients without informed consent

Design outcomes

Primary

Measure	Time frame
Comparison with the findings on cystoscopy and the results of photodynamic diagnosis using hexaminolevulinate every three months after transurethral resection of bladder cancer	—

Countries

Japan

Contacts

Public ContactYasushi Nakai

Nara Medical University Department of Urology

nakaiyasusiuro@live.jp0744223051

Outcome results